26 LANDSDOWNE STREET, CAMBRIDGE, MA
Reports First Quarter 2026 Financial Results and Recent Business Updates
Annual Report to Security Holders
Termination of License Agreement with Bio Palette Co., Ltd.
Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Material Contracts
Director Resignation - Carole Ho Steps Down from Beam Therapeutics Board
Investor Presentation
Bristol-Myers Squibb Completes Acquisition of Orbital Therapeutics
Q1
FY 2024
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Free Writing Prospectus